[Hospital Formulations for Palliative Medicine]

Area of Science:

• Palliative Care
• Oncology Pharmacy
• Pharmaceutical Compounding

Background:

• Palliative care is crucial for maintaining and improving cancer patients' quality of life (QOL).
• Managing complex symptoms in cancer patients, especially the elderly with comorbidities, often requires customized pharmaceutical solutions beyond commercial formulations.
• In-house pharmaceutical preparations (hospital formulations, HF) offer tailored symptomatic management but are resource-intensive and pose challenges in predicting drug quantities.

Purpose of the Study:

• To present examples of hospital formulations (HF) used in clinical practice for palliative care in oncology.
• To discuss the role and future necessity of HF, considering the shift towards outpatient oncology care.
• To highlight the potential of HF in symptom alleviation and QOL improvement for cancer patients.

Main Methods:

• Review of clinical practice examples involving hospital formulations (HF) for palliative cancer care.
• Discussion of the development pathway from HF to potential commercial products through physician-pharmacist collaboration.
• Analysis of the challenges and benefits associated with customized pharmaceutical preparations in oncology.

Main Results:

• Hospital formulations (HF) have demonstrated significant efficacy in alleviating symptoms and improving the QOL of cancer patients.
• The development of HF can serve as a precursor to new marketable pharmaceutical products, including commercial painkillers.
• Collaborations between physicians and pharmacists in developing HF have led to innovative pain management solutions.

Conclusions:

• Hospital formulations (HF) play a vital role in optimizing symptomatic management and enhancing QOL for cancer patients, particularly those with complex comorbidities.
• Despite challenges in preparation and resource allocation, HF can lead to significant clinical benefits and pharmaceutical innovation.
• Ensuring patient safety, obtaining informed consent, and diligent follow-up are paramount when utilizing hospital formulations in palliative cancer care, especially with the trend towards outpatient services.